We are live on !
Find out more
SC
Stempoint Capital Portfolio holdings
AUM
$581M
Turnover
56.9%
1-Year Est. Return
373.68%
This Fund
S&P 500
This Quarter Est. Return
+35.11%
1 Year Est. Return
+373.68%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$58.2M
(+11%)
Cap. Flow
-$54.7M
Cap. Flow % of AUM
Cap. Flow %
-9.43%
Top 10 Holdings %
Top 10 Hldgs %
40.99%
Holding
116
New
34
Increased
19
Reduced
30
Closed
32
Avg Time Held
Equity + Options
0.4
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.5
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tango Therapeutics
TNGX
|
+$25.3M |
| 2 |
Erasca
ERAS
|
+$19M |
| 3 |
Tyra Biosciences
TYRA
|
+$14.5M |
| 4 |
First Tracks Biotherapeutics
TRAX
|
+$11.6M |
| 5 |
Kiniksa Pharmaceuticals
KNSA
|
+$10.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$38.5M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$28.4M |
| 3 |
Revolution Medicines
RVMD
|
+$17.8M |
| 4 |
MBX Biosciences
MBX
|
+$14.9M |
| 5 |
Immunovant
IMVT
|
+$14.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.23% |
| 2 | Miscellaneous | 0.45% |
| 3 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Tango Therapeutics
TNGX
$3.97B
| $38.2M | 6.59% |
1,223,019
+1,022,100
| +509% | +$25.3M |
2026 Q1
1 quarter
|
|
2
Abivax
ABVX
$7.64B
| $37.8M | 6.51% |
283,657
-30,134
| -10% | -$3.41M |
2025 Q2
4 quarters
|
|
|
3
Revolution Medicines
RVMD
$39B
| $30M | 5.16% |
159,943
-121,689
| -43% | -$17.8M |
2025 Q3
3 quarters
|
|
|
4
Erasca
ERAS
$4.76B
| $28.7M | 4.94% |
1,565,913
+1,326,052
| +553% | +$19M |
2026 Q1
1 quarter
|
|
|
5
Tyra Biosciences
TYRA
$1.33B
| $20.2M | 3.48% |
632,754
+439,577
| +228% | +$14.5M |
2026 Q1
1 quarter
|
|
6
Dianthus Therapeutics
DNTH
$4.17B
| $19.6M | 3.37% |
200,851
+115,349
| +135% | +$10.1M |
2025 Q3
3 quarters
|
|
7
Enliven Therapeutics
ELVN
$2.84B
| $17.6M | 3.03% |
346,914
-16,524
| -5% | -$702K |
2026 Q1
1 quarter
|
|
8
Mineralys Therapeutics
MLYS
$1.85B
| $16.3M | 2.8% |
602,686
+69,308
| +13% | +$1.9M |
2025 Q2
4 quarters
|
|
9
Biohaven
BHVN
$1.71B
| $15.8M | 2.73% |
1,064,200
-530,291
| -33% | -$5.71M |
2026 Q1
1 quarter
|
|
10
Surrozen
SRZN
$280M
| $13.8M | 2.37% |
602,798
+77,159
| +15% | +$2.12M |
2024 Q2
8 quarters
|
|
|
11
Kiniksa Pharmaceuticals
KNSA
$6.2B
| $13.4M | 2.3% |
+209,234
| New | +$10.9M |
2026 Q2
0 quarters
|
|
|
12
Scholar Rock
SRRK
$4.9B
| $13.2M | 2.27% |
239,146
-796,350
| -77% | -$38.5M |
2024 Q4
6 quarters
|
|
13
Alkermes
ALKS
$7.21B
| $13M | 2.24% |
248,015
+167,523
| +208% | +$6.54M |
2026 Q1
1 quarter
|
|
|
14
First Tracks Biotherapeutics
TRAX
$1.3B
| $12.5M | 2.16% |
+622,723
| New | +$11.6M |
2026 Q2
0 quarters
|
|
15
Praxis Precision Medicines
PRAX
$7.26B
| $12.5M | 2.15% |
37,243
-19,024
| -34% | -$6.02M |
2025 Q4
2 quarters
|
|
16
Roivant Sciences
ROIV
$25.1B
| $12.3M | 2.12% |
348,408
-37,392
| -10% | -$1.1M |
2023 Q4
10 quarters
|
|
17
BioAge Labs
BIOA
$229M
| $11.4M | 1.96% |
464,171
+125,517
| +37% | +$2.27M |
2026 Q1
1 quarter
|
|
18
CG Oncology
CGON
$5.31B
| $11.3M | 1.95% |
159,349
-46,273
| -23% | -$3.02M |
2026 Q1
1 quarter
|
|
19
Oruka Therapeutics
ORKA
$4.93B
| $11.1M | 1.91% |
+116,461
| New | +$7.76M |
2026 Q2
0 quarters
|
|
|
20
Immunovant
IMVT
$5.7B
| $10.7M | 1.84% |
276,527
-469,967
| -63% | -$14.3M |
2023 Q4
10 quarters
|
|
21
Celcuity
CELC
$2.79B
| $10.3M | 1.77% |
98,203
+38,141
| +64% | +$4.4M |
2025 Q3
3 quarters
|
|
22
Relmada Therapeutics
RLMD
$337M
| $10.1M | 1.74% |
1,460,093
+862,684
| +144% | +$6.03M |
2026 Q1
1 quarter
|
|
23
Climb Bio
CLYM
$559M
| $9.7M | 1.67% |
+742,745
| New | +$7.67M |
2026 Q2
0 quarters
|
|
24
Spyre Therapeutics
SYRE
$7.92B
| $9.49M | 1.64% |
106,926
-60,680
| -36% | -$4.43M |
2025 Q4
2 quarters
|
|
25
Zura Bio
ZURA
$365M
| $8.07M | 1.39% |
1,368,215
+614,695
| +82% | +$2.93M |
2026 Q1
1 quarter
|
|
Similar funds
PM
RIS
GFI
CCWM
MFS
MIP
CA
LCM
Stempoint Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Stempoint Capital held 116 positions worth $581M, up 11% from $522M the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Stempoint Capital withdrew a net $54.7M in Q2 2026, closing 32 positions and reducing 30 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $28.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Stempoint Capital opened a new position in First Tracks Biotherapeutics worth $12.5M.
- Stempoint Capital's largest Q2 2026 buy was First Tracks Biotherapeutics: 622,723 shares worth $12.5M.
- Stempoint Capital added most to Tango Therapeutics in Q2 2026, an estimated $25.3M increase.
- Stempoint Capital's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $38.5M.
- Stempoint Capital fully exited Syndax Pharmaceuticals in Q2 2026, selling an estimated $28.4M.
- Stempoint Capital's ten largest holdings make up 41% of its $581M portfolio in Q2 2026.
- Stempoint Capital opened 34 new positions and closed 32 in Q2 2026.
- Stempoint Capital's portfolio value rose 11% quarter-over-quarter to $581M.
Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.